Result of General Meeting

RNS Number : 4273O

SkinBioTherapeutics PLC

31 January 2023

 

31 January 2023

SkinBioTherapeutics plc

Results of General Meeting

SkinBioTherapeutics plc   (AIM: SBTX or the "Company")   announces that at the Company's General Meeting, held yesterday 30 January 2023, all resolutions were duly passed.

Details of the proxy votes received on each resolution by the Company's Registrar are set out below:

Resolution			For & Discretionary		Against		Withheld
			Number of votes	%	Number of votes	%	Number of votes	%
1	The Directors' and Auditors' reports and the financial statements for the financial year ended 30 June 2022 be received and adopted		36,364,572	99.58%	117,330	0.32%	37,825	0.10%
2	Jeffreys Henry LLP be re-appointed as the auditors of the Company until the next Annual General Meeting of the Company		36,362,147	99.57%	129,755	0.36%	27,825	0.08%
3	The Directors be authorised to fix the auditors' remuneration		36,377,487	99.61%	114,415	0.31%	27,825	0.08%
4	To authorise the directors to allot shares		36,295,269	99.39%	193,322	0.53%	31,136	0.09%
5		Special resolution to authorise the directors to disapply pre-emption rights	36,257,227	99.28%	232,575	0.64%	29,925	0.08%
6		Special resolution to authorise the directors to disapply pre-emption rights in relation to an acquisition or other capital investment	36,310,509	99.43%	178,555	0.49%	30,663	0.08%

-Ends-

 For more information, please contact:

SkinBioTherapeutics plc Stuart J. Ashman, CEO Manprit Randhawa, CFO	Tel: [phone]
Cenkos Securities Plc (Nominated Adviser & Broker) Giles Balleny, Max Gould (Corporate Finance) Dale Bellis, Tamar Cranford-Smith (Sales)	Tel: [phone]
Instinctif Partners (financial press) Melanie Toyne-Sewell / Tim Field	Tel: [phone] SkinBioT herapeutics @instinctif.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com .

 

END

 

 

ROMFLFLLLIILVIV